About Inotec AMD
Inotec AMD is a Cambridge based company that was formed specifically to introduce a new technology to wound care specialists and health care providers around the world. NATROX® Oxygen Wound Therapy was designed to promote faster and better healing in patients with wounds.
Non Executive Directors
Dr Adrian Parton MBE
Adrian Parton is a Director of Objective Imaging Ltd (Hardware Software Automation business), AB-Polyblok Ltd (novel dementia drug), Toxibact Ltd (Novel antimicrobial) and Chairman/Owner of Ivy House Country House Hotel. He has a PhD in Molecular Virology and has been in industry for the last 25 years. He has successfully grown technology based businesses from concept through to production and into multi-national businesses.
Luigi Sala is Partner and Chairman with Charme Capital Partners, a private equity firm investing in management buy outs throughout Europe and the UK. He is also a passionate business angel in healthcare start ups.
Pierre Socha is an early stage technology investor with Amadeus Capital Partners. He invests in digital health, medical technologies, autonomous systems, augmented reality, cyber security and artificially intelligence. He currently sits on the boards of Doctify, Repositive, Lumeon, PhoreMost and Congenica.
Michael Clancy has 35 years’ experience in marketing, sales and general management within European medical devices with specialist knowledge and experience within the medical beds, pressure redistribution and wound care sectors. He is currently non-executive director at Medstrom Ltd and Inotec AMD Limited.
Cambridge Capital Group
Cambridge Capital Group is a leading business angel group of 40 investors that have been investing in hi-tech businesses for ten years.
Cambridge Enterprise Limited is a wholly owned subsidiary of the University of Cambridge, responsible for the commercialisation of University intellectual property.
The Cambridge Angels are a group of high-net worth investors who have proven experience as successful entrepreneurs in technology and bio-technology.
Amadeus Capital Partners
Amadeus Capital Partners is a global technology investor. Since its inception in 1997, the firm has raised over $1bn for investment and backed more than 100 companies in the software, mobile, internet, cyber security and medical technology sectors. The investment team is based in India, South Africa, Sweden, UK and USA, has deep experience in technology and invests in high-growth companies from early stage to pre-IPO.